Asarina Pharma AB (publ) (ASAP.ST)
SEK 0.03
(-31.03%)
SEK 0.03
(-31.03%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -14.21 Million SEK | -0.66% |
| 2022 | -14.12 Million SEK | 62.35% |
| 2021 | -37.89 Million SEK | 54.64% |
| 2020 | -82.7 Million SEK | -5.19% |
| 2019 | -81.48 Million SEK | -52.9% |
| 2018 | -51.42 Million SEK | -81.06% |
| 2017 | -28.4 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | -2.45 Million SEK | 0.0% |
| 2023 FY | - SEK | -0.66% |
| 2023 Q1 | -4.65 Million SEK | -43.74% |
| 2023 Q2 | -4.65 Million SEK | 0.0% |
| 2023 Q3 | -2.45 Million SEK | 47.23% |
| 2022 Q3 | -3.23 Million SEK | 13.77% |
| 2022 Q1 | -3.86 Million SEK | 48.14% |
| 2022 FY | - SEK | 62.35% |
| 2022 Q4 | -3.23 Million SEK | 0.0% |
| 2022 Q2 | -3.75 Million SEK | 2.97% |
| 2021 Q2 | -15.89 Million SEK | -155.18% |
| 2021 Q3 | -7.93 Million SEK | 50.06% |
| 2021 Q4 | -7.46 Million SEK | 6.0% |
| 2021 FY | - SEK | 54.64% |
| 2021 Q1 | -6.22 Million SEK | 76.55% |
| 2020 Q2 | -17.84 Million SEK | 2.01% |
| 2020 FY | - SEK | -5.19% |
| 2020 Q4 | -26.55 Million SEK | -55.5% |
| 2020 Q3 | -17.08 Million SEK | 4.27% |
| 2020 Q1 | -18.2 Million SEK | 22.94% |
| 2019 Q2 | -25.71 Million SEK | -175.57% |
| 2019 Q1 | -9.33 Million SEK | 56.48% |
| 2019 FY | - SEK | -52.9% |
| 2019 Q4 | -23.62 Million SEK | -18.45% |
| 2019 Q3 | -19.94 Million SEK | 22.45% |
| 2018 Q1 | -5 Million SEK | 29.65% |
| 2018 FY | - SEK | -81.06% |
| 2018 Q4 | -21.44 Million SEK | -46.48% |
| 2018 Q3 | -14.64 Million SEK | -50.2% |
| 2018 Q2 | -9.74 Million SEK | -94.82% |
| 2017 Q4 | -7.11 Million SEK | -100.17% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | -8.86 Million SEK | 0.0% |
| 2017 Q3 | -3.55 Million SEK | 59.93% |
| 2017 Q2 | -8.86 Million SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | 67.605% |
| Amniotics AB (publ) | -27.14 Million SEK | 47.622% |
| BioArctic AB (publ) | 275.38 Million SEK | 105.163% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 96.135% |
| Camurus AB (publ) | 562.54 Million SEK | 102.527% |
| Cantargia AB (publ) | -284.31 Million SEK | 95.0% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 27.386% |
| CombiGene AB (publ) | -35.33 Million SEK | 59.766% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 89.906% |
| Genovis AB (publ.) | 64.57 Million SEK | 122.017% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 87.627% |
| Mendus AB (publ) | -97.84 Million SEK | 85.47% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 61.601% |
| Intervacc AB (publ) | -68.98 Million SEK | 79.39% |
| Kancera AB (publ) | -61.88 Million SEK | 77.028% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 46.918% |
| LIDDS AB (publ) | -39.67 Million SEK | 64.162% |
| Lipum AB (publ) | -37.11 Million SEK | 61.699% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -17.457% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 145.271% |
| NextCell Pharma AB | -40.98 Million SEK | 65.312% |
| OncoZenge AB (publ) | 7.26 Million SEK | 295.665% |
| Saniona AB (publ) | -69.69 Million SEK | 79.601% |
| Simris Alg AB (publ) | -22.36 Million SEK | 36.426% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 95.522% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 94.959% |
| Xintela AB (publ) | -53.47 Million SEK | 73.412% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 91.628% |
| Ziccum AB (publ) | -20.34 Million SEK | 30.11% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 16.784% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 710950.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 94.017% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -583.51% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -5.852% |
| Corline Biomedical AB | -1.69 Million SEK | -740.745% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 91.797% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 74.059% |
| Aptahem AB (publ) | -10 Million SEK | -42.039% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 223.102% |
| Fluicell AB (publ) | -25.91 Million SEK | 45.138% |
| Biovica International AB (publ) | -119.5 Million SEK | 88.104% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 66.33% |
| AcouSort AB (publ) | -16.7 Million SEK | 14.884% |
| Abliva AB (publ) | -93.6 Million SEK | 84.812% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 95.545% |
| 2cureX AB (publ) | -35.13 Million SEK | 59.537% |
| I-Tech AB | 30.34 Million SEK | 146.851% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 98.01% |
| Cyxone AB (publ) | -20.41 Million SEK | 30.357% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 86.123% |
| Biosergen AB | 228 Thousand SEK | 6335.526% |
| Nanologica AB (publ) | -62.11 Million SEK | 77.113% |
| SynAct Pharma AB | -222.7 Million SEK | 93.616% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 67.586% |
| BioInvent International AB (publ) | -312.7 Million SEK | 95.454% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 4694.83% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 33950.806% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 93.862% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -61.328% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 86.904% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -23.96% |